N@N

Market Maker Surveillance Report. AVARF, CXZ, MPG, KOOL, ACUR, XOMA, Winning Stocks With Lowest Price Friction For Tuesday, De

^{Published on 2010-12-21 19:01:00, Last Modified on 2010-12-22 19:50:28 - WOPRAI}
 

December 21, 2010 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 2544 companies with "abnormal" market making, 3563 companies with positive Friction Factors and 1979 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. AVALON RARE METALS INC (OTC:AVARF), CROSSHAIR EXPLORATION & MINI (AMEX:CXZ), MPG OFFICE TRUST INC (NYSE:MPG), THERMOGENESIS CORP (NASDAQ:KOOL), ACURA PHARMACEUTICALS INC (NASDAQ:ACUR), XOMA LTD (NASDAQ:XOMA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

     Symbol     Change       Percent      Buy Volume      Buy %%       Sell Volume     Sell %%      Net Volume      Friction
     AVARF      $0.806       20.17%       560,361         36.41%       451,965         29.37%       108,396         1,346   
     CXZ        $0.350       25.00%       328,805         61.62%       189,191         35.46%       139,614         3,989   
     MPG        $0.350       14.89%       865,335         49.66%       635,442         36.46%       229,893         6,568   
     KOOL       $0.460       19.83%       252,805         51.91%       228,298         46.87%       24,507          533     
     ACUR       $0.700       23.65%       402,302         54.86%       322,673         44.00%       79,629          1,138   
     XOMA       $1.670       70.17%       6,258,528       52.98%       5,521,322       46.74%       737,206         4,414   

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows XOMA with a dollar gain Tuesday of $1.67000 and a Friction Factor of 4,414 shares. That means that it only took 4,414 more shares of buying than selling to move XOMA higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

AVALON RARE METALS INC (OTC:AVARF) - Avalon Rare Metals Inc. engages in the development and exploration of rare metals and minerals in Canada. The company primarily explores for lithium, beryllium, indium, gallium, and rare earth elements, such as neodymium and terbium; and rare minerals, including calcium feldspar. It holds interests primarily in the Thor Lake rare metals project located in the Mackenzie mining district of the Northwest Territories; Separation Rapids rare metals project and Warren Township Anorthosite project located in Ontario; and East Kemptville rare metals project located in Nova Scotia. The company was formerly known as Avalon Ventures Ltd. and changed its name to Avalon Rare Metals Inc. in February 2009. Avalon Rare Metals Inc. was founded in 1991 and is based in Toronto, Canada.

CROSSHAIR EXPLORATION & MINI (AMEX:CXZ) - Crosshair Exploration & Mining Corp. engages in the acquisition, exploration, and development of mineral properties, primarily uranium, base, and precious metals in North America. It focuses on exploration activities in the province of Newfoundland and Labrador, Canada; and the states of Wyoming and Utah, the United States. The company was formerly known as International Lima Resources Corp. and changed its name to Crosshair Exploration & Mining Corp. in March 2004. Crosshair Exploration & Mining Corp. was incorporated in 1966 and is headquartered in Vancouver, Canada.

MPG OFFICE TRUST INC (NYSE:MPG) - Maguire Properties, Inc., a real estate investment trust (REIT), engages in the ownership, management, acquisition, and development of office and real estate properties primarily in California. As of June 30, 2005, the company owned a portfolio of 25 commercial real estate properties, including 22 office and retail projects, a 350-room hotel, 6 off-site parking garages totaling approximately 5,969 spaces, and onsite structured and surface parking totaling approximately 26,549 spaces. It also owned undeveloped land that could support approximately 11.8 million square feet of office, retail, structured parking, and residential uses, as of the above date. The company has elected to be treated as a REIT under the Internal Revenue Code of 1986. As a REIT, it would not be subject to federal income tax, provided it distributes at least 90% of its taxable income to its shareholders. The company was founded in 1965 and is headquartered in Los Angeles, California.

THERMOGENESIS CORP (NASDAQ:KOOL) - ThermoGenesis Corp. operates as a supplier of products targeting the worldwide adult stem cell market. It offers automated and semi-automated devices, and single-use processing disposables that enable the collection, processing, and cryopreservation of stem cells and other cellular tissues from cord blood and bone marrow used in the practice of regenerative medicine. Regenerative medicine is a field that aims to repair or restore lost or damaged tissue and cell function using cell-based therapies. The companys core offerings include the AXP AutoXpress Platform for processing of cord blood; and BioArchive System, an automated cryogenic device used by cord blood banks for the cryopreservation and archiving of cord blood stem cell units for transplant. Its offerings also comprise MXP MarrowXpress, which is used for isolating stem cells from bone marrow, and the Res-Q 60 BMC, a point-of-care bone marrow stem cell processing system. In addition, ThermoGenesis markets the Thermoline product line, which includes the ultra-rapid plasma Thermoline Freezer and Thermoline Thawer. The company was founded in 1986 and is headquartered in Rancho Cordova, California.

ACURA PHARMACEUTICALS INC (NASDAQ:ACUR) - Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and manufacture of pharmaceutical product candidates utilizing its proprietary Aversion Technology, Impede Technology, and other technologies. Its Aversion Technology is a proprietary platform technology providing abuse deterrent features and benefits to orally administered pharmaceutical drug products containing abusable active ingredients, such as tranquillizers, stimulants, sedatives, decongestants, and various other opioid analgesics. The companys lead product candidate, Acurox Tablet, is an orally administered immediate release tablet containing oxycodone HCl as its active analgesic ingredient. Its opioid analgesic product candidates are used to relieve pain while discouraging common methods of opioid product misuse and abuse, including intravenous injection of dissolved tablets or capsules; nasal snorting of crushed tablets or capsules; and intentional swallowing of excess quantities of tablets or capsules. The company is also investigating and developing mechanisms to incorporate abuse deterrent characteristics into abused and misused pharmaceutical products through laboratory testing of a product candidate developed with its Impede Technology, which is intended to inhibit the conversion of pseudoephedrine HCl into methamphetamine. Acura Pharmaceuticals, Inc. has a license, development, and commercialization agreement with King Pharmaceuticals Research and Development, Inc. to develop and commercialize various opioid analgesic products utilizing the companys proprietary Aversion Technology in the United States, Canada, and Mexico. The company was founded in 1935 and is based in Palatine, Illinois.

XOMA LTD (NASDAQ:XOMA) - XOMA Ltd., incorporated in 1981, is a biopharmaceutical company in the field of therapeutic antibody discovery and development. The Company has a royalty interest in one approved therapeutic antibody, RAPTIVA, which is marketed in the United States, Europe and elsewhere, for the treatment of moderate-to-severe plaque psoriasis. XOMA also has a future royalty interest in additional therapeutic antibody product candidates being developed by others as a result of licensing its technologies. XOMA's pipeline includes both products and collaborative programs at various stages of preclinical and clinical development primarily directed toward treatments for cancer and immune disorders. In addition to supporting its product pipeline, the Company uses its infrastructure to provide process development and manufacturing services on a fee-for-service basis.

RAPTIVA (Efalizumab)

The Company markets RAPTIVA under an agreement with Genentech, Inc. as a result of a prior collaborative product development program. RAPTIVA is a humanized therapeutic monoclonal antibody developed to treat immune system disorders. RAPTIVA can be self-administered by patients as a single, once-weekly subcutaneous injection. In 2005, Serono had launched RAPTIVA in over 40 countries worldwide.

RAPTIVA competes with Enbrel from Amgen Inc. and its partner Wyeth Pharmaceuticals; Amevive from Biogen Idec Inc.; BG-12 from Biogen Idec Inc. and Fumapharm AG; Remicade from Centocor, Inc. Humira from Abbott Laboratories, and ISA247 from Isotechnika, Inc.

CHIR-12.12

CHIR-12.12, which is being developed by the Company in collaboration with Chiron Corporation, is an anti-CD40 antagonist antibody intended as a treatment for B-cell malignancies. In April 2005, XOMA announced the initiation of Phase I study for patients with advance chronic lymphocytic leukemia (CLL). Then in October 2005, the Company initiated a second Phase I study for patients with multiple myeloma (MM).

NEUPREX (opebacan/rBPI21)

NEUPREX (opebacan/rBPI21) is an injectable formulation of rBPI21, a modified recombinant fragment of human bactericidal/permeability-increasing protein (BPI). BPI is a human host-defense protein made by a type of white blood cell that is involved in the body's defenses against microbial infection. In October of 2003, in conjunction with Children's Medical Center Dallas, the Company announced the initiation of an open-label, single center, dose escalation, investigator-sponsored, Phase I/II clinical trial of NEUPREX in pediatric patients with congenital heart abnormalities requiring open heart surgery associated with cardiopulmonary bypass.

XMA005.2

XMA005.2 is a Human Engineered monoclonal antibody with a high-affinity and potent inhibitory activity against its inflammatory target. This high potency means that it may be suitable for use as a monthly-dose injectable therapeutic. XOMA is evaluating XMA005.2 in preclinical studies targeting multiple indications, including osteoarthritis and rheumatoid arthritis, where less frequent dosing could be a significant marketing advantage.

Anti-gastrin Mab

In September of 2004, XOMA announced a worldwide collaboration with Aphton Corporation to develop treatments for gastrointestinal (GI) and other gastrin-sensitive cancers using anti-gastrin monoclonal antibodies. Gastrin has been shown to be involved in the progression of colorectal, stomach, liver and pancreatic cancers and inhibiting gastrin may inhibit such growth.

Metabolic Disease Target

The Company is co-developing Metabolic Disease Target with Lexicon Genetics. Metabolic Disease Target is a secreted protein involved in metabolic functions such as insulin sensitivity and weight gain that was identified through Lexicon's Knockout Technology. Antibodies to this target may be developed to treat Type II diabetes, obesity and other metabolic diseases.

MLN2222

MLN2222 (also known as CAB2) is being developed by XOMA in partnership with Millennium Pharmaceuticals, Inc. MLN2222 is a complement inhibitor for coronary artery bypass graft surgery tar

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net